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Peroxisome proliferator-activated receptor α (PPARα) is a member of the steroid hormone receptor superfamily and is well known
toactasthemoleculartargetforlipid-loweringdrugsoftheﬁbratefamily.Atthemolecularlevel,PPARαregulatesthetranscription
of a number of genes critical for lipid and lipoprotein metabolism. PPARα activators are further shown to reduce body weight
gain and adiposity, at least in part, due to the increase of hepatic fatty acid oxidation and the decrease in levels of circulating
triglycerides responsible for adipose cell hypertrophy and hyperplasia. However, these eﬀects of the PPARα ligand fenoﬁbrate on
obesity are regulated with sexual dimorphism and seem to be inﬂuenced by the presence of functioning ovaries, suggesting the
involvement of ovarian steroids in the control of obesity by PPARα. In female ovariectomized mice, 17β-estradiol inhibits the
actions of fenoﬁbrate on obesity through its suppressive eﬀects on the expression of PPARα target genes, and these processes
may be mediated by inhibiting the coactivator recruitment of PPARα. Thus, it is likely that PPARα functions on obesity may be
enhanced in estrogen-deﬁcient states.
1.Introduction
Obesity is the result of an energy imbalance caused by
an increased ratio of caloric intake to energy expenditure.
In conjunction with obesity, related metabolic disorders
such as dyslipidemia, atherosclerosis, and type 2 diabetes
have become global health problems. The peroxisome
proliferator-activated receptors (PPARs) have been the sub-
ject of intense investigation and considerable pharmaco-
logical research due to the fact that they are involved in
the improvement of these chronic diseases. Three PPAR
isotypes have been identiﬁed: PPARα,P P A R γ,a n dP P A R β/δ,
each with diﬀerent ligand speciﬁcity, very distinct tissue
distributions, and diﬀerent biological functions.
Among the three subtypes, PPARα is expressed predom-
inantly in tissues that have a high level of fatty acid (FA)
catabolism such as liver, heart, and muscle [1–3]. PPARα
regulates the expression of a large number of genes that
aﬀectlipidandlipoproteinmetabolism[4–7].PPARαligands
ﬁbrates have been used for the treatment of dyslipidemia
due to their ability to lower plasma triglyceride levels and
elevate HDL cholesterol levels. PPARα is also thought to be
involved in energy metabolism. Since PPARα ligands ﬁbrates
stimulate hepatic FA oxidation and thus reduce the levels of
plasma triglycerides responsible for adipose cell hypertrophy
and hyperplasia, PPARα may be important in the control of
adiposity and body weight due to its ability to regulate an
overall energy balance. This notion is supported by ﬁndings
showing that PPARα-deﬁcient mice exhibited abnormalities
in triglyceride and cholesterol metabolism and became obese
with age [8]. Furthermore, several studies have suggested
that ﬁbrates can modulate body weight and adiposity in
experimental animal models, such as fatty Zucker rats, high
fat-fed C57BL/6 mice, and high fat-fed obese rats [9–11].
Energy balance seems to be inﬂuenced by gonadal
sex steroids [12]. Female sex steroid hormones have been
the subject of intense investigation over the last several
decades based on the role that these ovarian hormones
play in regulating food intake, body weight, and lipid
metabolism. For example, ovariectomized (OVX) animals
and postmenopausal women show increased food intake,
body weight, andadipose tissue mass,aswell asdecreasedFA
oxidation and triglyceride lipolysis, indicating the involve-
ment of gonadal steroids in the modulation of obesity [13–
16]. Several lines of study show that ovarian steroids, in par-
ticular estrogens, can aﬀect obesity and the related disorders2 PPAR Research
of dyslipidemia, type 2 diabetes, and cardiovascular disease
(CVD) [12]. Estrogen insuﬃciency is known to be largely
responsible for increased adiposity and circulating lipids in
OVX rodents because such animals do not display obesity,
adiposity, and lipid disorders when they are administered
exogenous estrogens [17–19]. Moreover, my previous results
demonstrated that fenoﬁbrate reduced body weight and
white adipose tissue (WAT) mass in male and female OVX
mice [20–23]. Although the administration of 17β-estradiol
(E2)orfenoﬁbratealoneeﬀectivelyreducesbodyweightgain
and WAT mass in female OVX mice, fenoﬁbrate treatment
does not prevent gains in body weight and WAT mass in the
presence of ovaries. Interestingly, there are data indicating
that PPAR/RXR heterodimers are capable of binding to
estrogen response elements (EREs), and PPAR and estrogen
receptors (ERs) share cofactors [24–28], suggesting that
signal cross-talk may exist between PPARα and ERs in the
control of obesity.
Based on my published results showing the fenoﬁbrate
functions on obesity during various conditions, this paper
will focus on the diﬀerential regulation of PPARα on obesity
by sex diﬀerences and the interaction of PPARα and ERs in
the regulation of obesity.
2. GeneralAspects of PPARαandERs
2.1. PPARα and ERs as Nuclear Hormone Receptors. Both
PPARα and ERs belong to the nuclear hormone receptor
superfamily, which has a typical structure consisting of six
functional domains, A/B, C, D, and E/F (Figure 1)[ 29–
31]. The amino-terminal A/B domain contains a ligand-
independent activation function-1 (AF-1). The C or DNA
bindingdomain(DBD)containsthestructureofthetwozinc
ﬁngers and α-helical DNA motifs. The DBD directs nuclear
receptorstothehormoneresponseelements(HREs)oftarget
genes. The D region is a highly ﬂexible hinge region and may
be involved in protein-protein interactions, such as receptor
dimerization and eﬃcient binding of DBD to HREs. The
E/F domain is responsible for ligand-binding and is thus
named the ligand binding domain (LBD). The interaction of
nuclear receptors with their ligands induces conformational
changes that include the AF-2 ligand-dependent activation
domain, which is located in the C-terminal α-helix. AF-2
regulates ligand-dependent transactivation, recruitment of
coactivators, and release of corepressors. In addition, AF-2
is also important for receptor dimerization.
Molecular signaling of PPARα and ERs functions is
similar [34–37]. In the unliganded or antagonist-bound
state, they are associated with corepressor proteins such as
nuclear receptor corepressor (NCoR) or silencing mediator
of retinoic acid and thyroid hormone receptor (SMRT)
(Figure 2(a)). After binding within the LBD, PPARα ligands
induce heterodimerization with retinoid X receptor (RXR)
and the subsequent interaction with coactivators like CREB-
binding protein (CBP) or steroid receptor coactivators,
followed by binding to PPAR response elements (PPREs)
withintargetgenepromoters(Figure 2(b)).Similarly,ligand-
activated ERs bind to their half-site-containing EREs as
homodimers following the recruitment of coactivators.
Importantly, PPARα shares a similar pool of cofactors with
ERs which provides a basis for mutual interactions between
these receptors [34, 35].
2.2. PPARα. PPARα was the ﬁrst PPAR to be identiﬁed by
Issemann and Green in 1990, and human PPARα was cloned
by Sher et al. in 1993 [1, 38]. PPARα is predominantly
expressed in tissues with high rates for mitochondrial and
p e r o x i s o m a lF Ac a t a b o l i s ms u c ha sl i v e r ,b r o w na d i p o s e
tissue (BAT), heart, skeletal muscle, kidney, and intestinal
mucosa [1–3]. Signiﬁcant amounts of PPARα are present in
diﬀerent immunological and vascular wall cell types [39, 40].
PPARα acts as a ligand-activated transcription factor.
PPARα mediates the physiological and pharmacological
signaling of synthetic or endogenous PPARα ligands. FAs
and FA-derived compounds are natural ligands for PPARα.
Modiﬁed FAs, conjugated FAs, oxidized phospholipids,
and FA-derived eicosanoids such as 8-S-hydroxytetraenoic
acid and leukotriene B4 activate PPARα [41]. Synthetic
compounds can also activate PPARα. These compounds
include carbaprostacyclin, nonsteroidal anti-inﬂammatory
drugs, pirinixic acid (also known as Wy14,643), phthalate
ester plasticizers, and hypolipidemic drugs ﬁbrates [41].
Of the currently used ﬁbrates, fenoﬁbrate, gemﬁbrozil,
cloﬁbrate, and ciproﬁbrate preferentially activate PPARα
whereasbezaﬁbrateactivatesallthreePPARs.NovelPPARα/γ
dual agonists and PPARα/γ/δ pan agonists with PPAR
selective modulator activity are under development as drug
candidates [42, 43].
PPARα regulates the expression of a number of genes
critical for lipid and lipoprotein metabolism, thereby leading
to lipid homeostasis. Ligand-bound PPARα heterodimerizes
with RXR and binds to direct repeat PPREs in the promoter
region of target genes (Figure 3(a)). PPARα target genes
include those involved in the hydrolysis of plasma triglyc-
erides,FAuptakeandbinding,andFAβ–oxidation(Table 1).
Genes involved in the HDL metabolism are also regulated
by PPARα. The activation of PPARα target genes therefore
promotes increased β-oxidation of FAs, as well as the
decrease in high circulating triglyceride levels and increased
high HDL cholesterol levels, leading to lipid homeostasis.
In addition to PPARα regulation of genes for lipid and
lipoprotein metabolism, PPARα regulates the expression of
uncoupling proteins (UCPs), which contain PPRE in their
promoters. PPARα activators increase the mRNA levels of
UCP1 in BAT, UCP2 in liver, and UCP3 in skeletal muscle.
UCP1 regulates energy expenditure through thermogenesis.
Reductions in body weight and adiposity by fenoﬁbrate
are associated with elevation of hepatic UCP2 expression
[44]. Transgenic mice overexpressing UCP3 in their skeletal
muscle exhibit increased FA oxidation and are resistant
to diet-induced obesity. Thus, PPARα may be involved in
energy balance and obesity by regulating UCPs [45].
In addition to the important roles of PPARα in FA oxida-
tion in liver and skeletal muscle, PPARα activators may aﬀect
adipose tissue metabolism. For example, administration of
bezaﬁbrate, a typical PPAR activator, leads to dediﬀeren-
tiation of adipocytes into preadipocyte-like cells throughPPAR Research 3
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Figure 1: Schematic structure of the functional domains of nuclear receptors. The activation domains AF-1 and AF-2 are located at the N-
terminal and C-terminal regions, respectively. C domain is a highly conserved DNA-binding domain. D domain is a highly ﬂexible hinge
region. E/E domain is responsible for ligand-binding and converting nuclear receptors to active forms that bind DNA. Adapted from [29].
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NR NR
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Figure 2: Activation and repression of nuclear receptor activity. (a)
In the absence of ligand, nuclear receptors (NRs) are associated
with corepressor complexes that bind Sin3 and histone deacetylase
(HDAC), thereby turning oﬀ gene transcription. Some steroid
receptors can recruit this complex when they are occupied by
antagonists although they do not seem to be associated with
corepressors in the unliganded state. (b) In the presence of
ligand, NRs generally recruit coactivator complexes, PCAF histone
acetyltransferase protein, general transcription factors, and RNA
polymerase II to induce gene transcription. GTF: general transcrip-
tion factor; RNA pol II: RNA polymerase II; PCAF: P300/CBP-
associated factor.
the activation of genes involved in both mitochondrial and
peroxisomalβ-oxidation[46].ThePPARαligandGI259578A
decreases the mean size of adipocytes in WAT [47]. This is
supported by my recent report that fenoﬁbrate stimulates
FA β–oxidation in both epididymal adipose tissue and
diﬀerentiated 3T3-L1 adipocytes [48].
Table 1: PPARα target genes involved in lipid homeostasis.
Target genes Gene
expression
Fatty acid uptake, binding, and activation
Fatty acid transport protein (FATP) Stimulation
Fatty acid translocase (FAT/CD36) Stimulation
Liver cytosolic fatty acid-binding protein
(L-FABP)
Stimulation
Acyl-CoA synthetase (ACS) Stimulation
Carnitine palmitoyltransferase I and II
(CPT-1and CPT-II)
Stimulation
Mitochondrial fatty acid β-oxidation
Very long-chain acyl-CoA dehydrogenase
(VLCAD)
Stimulation
Long chain acyl-CoA dehydrogenase (LCAD) Stimulation
Medium-chain acyl-CoA dehydrogenase
(MCAD)
Stimulation
Short-chain acyl-CoA dehydrogenase (SCAD) Stimulation
Peroxisomal fatty acid β-oxidation
Acyl-CoA oxidase (ACOX) Stimulation
Bifunctional enzyme (HD) Stimulation
3-Ketoacyl-CoA thiolase (Thiolase) Stimulation
Hydrolysis of plasma triglycerides
lipoprotein lipase (LPL) Stimulation
Apolipoprotein C-III (Apo C-III) Inhibition
Fatty acid synthesis
Acetyl-CoA carboxylase (ACC) Inhibition
Fatty acid synthase (FAS) Inhibition
HDL metabolism
Apolipoprotein A-I and A-II (ApoA-I and
ApoA-II)
Stimulation
ATP-binding cassette transporter 1 (ABCA1) Stimulation
Electron transport chain
Uncoupling protein 1, 2, and 3 (UCP1, 2, and 3) Stimulation4 PPAR Research
PPARα RXR Cytoplasm
9 cis-retinoic acid
RXR
Fibrates
PPARα
PPRE
Nucleus
AGGTCA-N1.2-AGGTCA Target gene
(a)
Nucleus
ER ER
Cytoplasm
ER
ER
Estrogens
ER
ERE
AGGTCA-N3-TGACCT Target gene
(b)
Figure 3: The signaling pathways of PPARαa n de s t r o g e nr e c e p t o r s .(a) After activation by its respective ligands, PPARα heterodimerizes with
retinoid X receptor and binds to direct repeat PPRE in the promoters of target genes to drive expression of target genes. (b) Estrogen-bound
estrogen receptors recognize palindromic ERE to directly bind this DNA and ultimately increase gene expression. RXR: retinoid X receptor;
PPRE: PPAR response element; ERE: estrogen response element; ERs: estrogen receptors.
PPARα may be involved in the regulation of energy
balance through fat catabolism. Since fenoﬁbrate increases
hepatic FA oxidation and thus decreases the levels of plasma
triglycerides responsible for adipose cell hypertrophy and
hyperplasia, it may inhibit an increase in body weight.
This is supported by a report that PPARα-deﬁcient mice
showed abnormal triglyceride and cholesterol metabolism
and became obese with age [8]. Expression of PPARα and
FA oxidative PPARα target genes is suppressed in obese mice
[49]. Many studies show that fenoﬁbrate can modulate body
weight in animal models of diabetes, obesity, and insulin
resistance although another known PPARα stimulator per-
ﬂuorooctanoic acid induces overweight at low doses in intact
female mice [9–11, 50].
PPARα also regulates insulin resistance and diabetes due
to visceral obesity. Fenoﬁbrate prevents adipocyte hypertro-
phy and insulin resistance by increasing FA β-oxidation and
intracellular lipolysis from visceral adipose tissue, showing
that PPARα may be one of the major factors leading to
decreased adipocyte size and improved insulin sensitivity
[48]. Moreover, PPARα agonist treatment has been reported
to improve pancreatic β-cell function in insulin-resistant
rodents and the adaptive response of the pancreatic β-cell
function to pathological conditions, such as obesity [51, 52].
In addition, PPARα agonists, including ﬁbrates, normalize
atherogenic lipid proﬁle, as well as several cardiovascularrisk
markers [53].
2.3. ERs. Like PPARα, ERs function as ligand-dependent
transcription factors belonging to members of the nuclear
hormone receptor family. Two major ERs (ERα and ERβ)
mediate the physiological and pharmacological signals of
natural or synthetic ER activators. Upon estrogen binding,
E R sa r ea c t i v a t e da n da c ta st r a n s c r i p t i o n a lm o d u l a t o r sb y
binding to palindromic EREs in the promoter region of
target genes (Figure 3(b))[ 54, 55]. ERs are also activated by
speciﬁc synthetic ligands such as raloxifene, tamoxifen, and
the ERβ-speciﬁc ligand diarylpropionitrile. ERα is mainly
expressed in the female reproductive system such as ovary,
uterus, pituitary, and mammary glands but is also present inPPAR Research 5
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Figure 4: Eﬀects of fenoﬁbrate on high fat diet-induced body weight gain (a) and WAT mass (b) in both sexes of C57BL/6 mice. Male and female
C57BL/6 mice were received a low fat, high fat, or high fat diet supplemented with fenoﬁbrate (0.05% w/w) for 13 weeks. Body weight at the
end of the experiment are statistically diﬀerent (P<. 01) between high fat diet and high fat plus fenoﬁbrate groups. # : Signiﬁcantly diﬀerent
versus a low fat diet group, P<. 05. ∗ : Signiﬁcantly diﬀerent versus a high fat diet group, P<. 01. Adapted from [20].
the hypothalamus, brain, bone, liver, WAT, skeletal muscle,
and the cardiovascular system [56–58]. ERβ is expressed in
many tissues including skeletal muscle, WAT, BAT, prostate,
salivary glands, testis, ovary, vascular endothelium, the
immune system, and certain neurons of the central and
peripheral nervous system [59, 60].
The natural forms of estrogens are E2, estrone, and
estriol. E2 potently activates ER-mediated transcriptional6 PPAR Research
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Figure5:Diﬀerentialregulationofbodyweightgain(a)andPPARαtargetgeneexpression(b)byfenoﬁbratedependingonthepresenceofovaries.
Female sham-operated (Sham) and ovariectomized (OVX) mice received a low fat, high fat, or fenoﬁbrate-supplemented (FF; 0.05% w/w)
high fat diet for 13 weeks. Body weights at the end of the treatment period are signiﬁcantly diﬀerent not only when comparing the low fat
group to either the high fat (P<. 05) or high fat plus FF (P<. 01) groups in female Sham mice, but also when comparing the high fat group
to either the low fat (P<. 01) or high fat plus FF (P<. 005) groups in female OVX mice. ∗ : Signiﬁcantly diﬀerent versus the high fat group,
P<. 05. # : Signiﬁcantly diﬀerent versus the Sham group, P<. 05. ACOX: acyl-CoA oxidase; HD: enoyl-CoA hydratase/3-hydroxyacyl-CoA
dehydrogenase; thiolase: 3-ketoacyl-CoA thiolase; apo C-III: apolipoprotein C-III. Adapted from [23].PPAR Research 7
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Figure 6: Inhibition of PPARα reporter gene expression ((a) and (b)) and coactivator recruitment (c) by 17 β-estradiol. (a) NMu2Li cells were
transiently transfected with expression plasmids for PPARα and PPRE3-TK-Luc reporter. ∗ Signiﬁcantly diﬀerent versus control group,
P<. 0001. # : Signiﬁcantly diﬀerent versus PPARα group P<. 0001. @ Signiﬁcantly diﬀerent versus PPARα/Wy group, P<. 001. (b)
NMu2Li cells were transiently transfected with expression plasmids for PPRE3-TK-Luc reporter and ERα or ERβ.∗: Signiﬁcantly diﬀerent
versus control group, P<. 05.# : Signiﬁcantly diﬀerent versus respective ER group, P<. 01. (c) CV-1 cells were transiently transfected with
expression plasmids for VP16-mPPARα, GAL-CBP, reporter plasmid pFR-Luc, and VP16-hERα or VP16-hERβ. #: Signiﬁcantly diﬀerent
versus PPARα group, P<. 01.∗ : Signiﬁcantly diﬀerent versus PPARα/Wy group, P<. 005. Adapted from [32].
activity to a greater extent than estrone or estriol. E2
has been considered one of the most important hor-
mones in female physiology and reproduction for a long
period. However, we now know that E2 also plays a
protective role in a variety of pathophysiological states,
such as obesity, cardiovascular disease, hyperlipidemia, dia-
betes, osteoporosis, and cancer in both men and women
[61].
E2 is involved in the regulation of adiposity and obe-
sity, and visceral fat varies inversely with E2 levels [62].
Accumulation of visceral fat occurs in females when E2
levels become suﬃciently low. In rodents, ovariectomy leads
to weight gain primarily in the form of adipose tissue,
which is reversed by physiologic E2 replacement [12, 63–
65]. Loss of circulating E2 is associated with an increase
in adiposity during menopause whereas postmenopausal8 PPAR Research
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Figure 7: Mechanism of inhibitory eﬀect of 17β-estradiol on PPAR α-mediated regulation of obesity. (a) Competition between PPARα and
estrogen receptors (ERs) for coactivator binding. 17β-estradiol-activated ERs can interfere with the PPRE binding of PPARα. (b) Inhibition
of PPARα actions on obesity by E.E impairs the ability of PPARα ligands to reduce body weight gain and adiposity in female ovariectomized
(OVX) mice. FF: fenoﬁbrate; RA: 9 cis-retinoic acid; RXR: retinoid X receptor. Adapted from [33].
women who receive E2 replacement therapy do not display
the characteristic abdominal weight gain pattern usually
associated with menopause [13–15]. Aromatase deﬁciency,
during which E2 is not produced, results in the development
of adiposity and obesity [66]. Furthermore, ERα deﬁciency
increased adipose tissue in both male and female mice,
consistent with other reports linking estrogen with body
weight regulation and adipocyte function [67]. E2 inﬂuences
food intake and eventually the maintenance of normal body
weight in adult females. In female dogs, a phasic decrease
in food intake occurs during estrus [68]. Gradual decreases
in eating through the follicular phase have been shown
in monkeys, which show progressive increases in estrogens
through the follicular phase comparable to those of humans
[69]. E2 treatment to OVX rats normalized meal size, food
intake, and body weight gain to the levels observed in intact
rats [19, 70]. ERβ is involved in the anorectic action of E2.
Blockade of ERβ inhibits the eﬀects of E2 on food intake,
body weight gain, and fat accumulation in OVX rats [71].
In contrast, Heine et al. [67] and D’Eon et al. [16]s u g g e s t e d
that E2 decreases adiposity and adipocyte size in OVX
mice independent of diﬀerences in energy intake, possibly
through promoting fat oxidation and enhancing triglyceride
breakdown [16, 67].
In addition to food intake and body weight regulation,
estrogen improves glucose homeostasis and diabetes melli-
tus. Mice that lack ERα have insulin resistance and impaired
glucose tolerance [67]. Both male and female aromatase-KO
mice have reduced glucose oxidation, and male aromatase-
KO mice develop glucose and insulin resistance that can be
reversed by E2 treatment [58, 66]. ERα and ERβ modulate
glucose transporter 4 expression and stimulate glucose
uptake in skeletal muscle of mice [58] .E s t r o g e n sh a v ea l s o
been shown to regulate vascular disease. Premenopausal
women have a lower tendency to develop hypertension
than do men of similar age, but the prevalence of CVD
increases more rapidly in aging women than in men [72].
The increased incidence of CVD in aged women may be due
to the development of obesity. Although the rate of increase
of CVD is greater at the postmenopausal age in women than
at the same age in men, the actual incidence of CVD is still
less in women than in men if hypertension is not included
(Framington Heart Study). Thus, estrogen signaling through
ERs leads to improvement of metabolic disorders.
As mentioned above, both PPARα and ERs have similar
structures, action mechanisms, and functions, suggesting
the interaction of PPARα with ERs in the control of these
metabolic diseases including obesity. However, signal cross-
talk between PPARα and ERs in the regulation of obesity is
not clear.
3. PPARα Functions on Obesity
Over the last several decades, a number of studies have been
published on the physiology, pharmacology, and functional
genomics of PPARα. In vivo and in vitro studies demonstrate
that PPARα plays a central role in lipid and lipoprotein
metabolism, and thereby decreases dyslipidemia associated
with metabolic syndrome. Obesity is the leading cause for
thedevelopmentofmetabolicdiseases,suchasobesity,type 2
diabetes, dyslipidemia, and CVD. There are important sex
diﬀerences in the prevalence of obesity-related metabolic
diseases [33, 73–75]. Ovarian hormones seem to have
protective roles in metabolic diseases since women with
functioning ovaries have much fewer incidences of such
disorders, but these metabolic diseases dramatically increase
in postmenopausal women.PPAR Research 9
3.1. Fenoﬁbrate Regulates Obesity with Sexual Dimorphism.
PPARα activator fenoﬁbrate diﬀerentially inﬂuences body
weight and adiposity in both sexes of mice. Fenoﬁbrate
improves body weight gain and adiposity in high fat-
diet-fed male mice, but fails to regulate them in female
mice (Figure 4)[ 20]. In males, body weight and WAT
mass increased by 44% and 77%, respectively, after 14-
week administration of high fat diet. These parameters
were lowered after fenoﬁbrate treatment, more so than
those of mice given a low fat diet, and the reduction in
body weight correlated with a fall in adipose tissue mass.
In contrast to males, fenoﬁbrate slightly increased high
fat diet-induced body weight and adipose tissue mass in
female mice, suggesting a diﬀerent PPARα action on females
than on males in the control of obesity. Previous studies
showed that fenoﬁbrate can modulate body weight and
adiposity in several animal models [9–11]. Since these results
were obtained from males, fenoﬁbrate may be an eﬀective
regulator of energy homeostasis in the male animal system.
Taken together, these studies show that body weight gain and
adipose tissue mass of male C57BL/6 mice were signiﬁcantly
reduced by fenoﬁbrate, but those of females were not, and
indicate that the action of fenoﬁbrate on body weight and
adiposity is diﬀerent, depending on sex.
Although ﬁbrates are drugs widely used to lower elevated
plasma triglycerides and cholesterol, fenoﬁbrate is shown to
control lipid metabolism with sexual dimorphism. Serum
concentrations of total cholesterol and triglycerides were
signiﬁcantly reduced by fenoﬁbrate in male mice, similar
to the previous reports [76, 77]. However, fenoﬁbrate not
only failed to decrease total cholesterol, but also decreased
circulating level of triglycerides in female mice to a much
lower extent than in similarly treated males. Based on the
information that lipids accumulated in the adipose tissue
are largely derived from circulating triglycerides, diﬀerential
regulation of adiposity by fenoﬁbrate is partly due to
diﬀerent levels of circulating lipids between sexes.
The regulatory eﬀect of fenoﬁbrate on obesity is not
mediated through leptin since PPARα-knockout mice that
become obese with age are not hyperphagic [8, 10]. Instead,
many reports indicate that fenoﬁbrate-regulated increases in
hepaticβ-oxidationareinvolvedinthisprocess.FAoxidation
results in a decrease in FAs available for triglyceride synthesis
[78, 79]. According to Yoon et al. [20], fenoﬁbrate elevated
the transcriptional activation of PPARα target genes, acyl-
CoA oxidase (ACOX), enoyl-CoA hydratase/3-hydroxyacyl-
CoA dehydrogenase (HD), and thiolase in both sexes of mice
[20]. However, the expression levels were much higher in
males than in females, suggesting that fenoﬁbrate exhibits
sexually dimorphic activation of PPARα actions on hepatic
β-oxidation, resulting in the diﬀerential energy balance with
sex.
Mancini et al. [11] and Guerre-Millo et al. [10]r e p o r t
that fenoﬁbrate improves obesity due to its action on FA
β-oxidation in the liver and seems to act as a weight-
stabilizer through its eﬀect on liver metabolism [10, 11].
Moreover, the body weights of PPARα-deﬁcient mice were
greater than those of wild-type mice, and a marked increased
amount of intra-abdominal adipose tissue was seen in
PPARα-KO mice. In addition, Costet et al. [8] suggested the
involvement of PPARα with a sexually dimorphic control of
circulating lipids, fat storage, and obesity, in a study using
male and female PPARα-null mice [8]. In contrast to these
investigators, Akiyama et al. [80]p r o v i d e de v i d e n c et h a t
PPARα regulates lipid metabolism but is not associated with
obesity [80]. Similar to the results of Akiyama et al. [80],
Yoon et al. [20]providedevidencethatfenoﬁbrateisinvolved
in obesity, but not likely to have an eﬀect on obesity mainly
through PPARα-mediated action since it increases FA β-
oxidation and decreases serum triglycerides in female mice,
although their eﬀects are much lower compared with males
[20].
Overall, fenoﬁbrate treatment aﬀects body weight, adi-
pose tissue mass, lipid metabolism, and hepatic β-oxidation
with sexual dimorphism, but fenoﬁbrate-regulated obesity is
notdirectlyassociatedwithPPARα-mediatedactionandmay
be inﬂuenced by sex-related factors.
3.2. Fenoﬁbrate Improves Male Obesity. Fenoﬁbrate seems
to suppress diet-induced obesity and severe hypertriglyc-
eridemia caused by LDL receptor (LDLR) deﬁciency in male
mice. The loss of LDLR increases susceptibility to diet-
induced obesity and hypertriglyceridemia. Body weights and
WAT mass increased in LDLR-null mice on a high fat diet
compared with low fat diet controls [22, 81]. However,
fenoﬁbrate prevented the high fat diet-induced increases in
body weight and WAT mass in male LDLR-null mice. The
body weights of male LDLR-null mice were signiﬁcantly
reduced after 1 week of fenoﬁbrate administration whereas
wild-type mice showed weight decreases after 7 weeks
of fenoﬁbrate [20, 22], indicating that fenoﬁbrate more
eﬀectively reduces body weight gain in LDLR-null mice than
in wild-type mice. Interestingly, the ﬁnal body weight of the
fenoﬁbrate-treated obese animals was very similar to that
of lean animals on a lowfat diet. High fat diet-fed LDLR-
null mice showed hepatic lipid accumulation, which was
absent in the hepatocytes of mice on a low fat diet and
which disappeared following fenoﬁbrate treatment, mainly
due to peroxisomal and mitochondrial β-oxidation of FAs
[82, 83]. This indicates not only the prevention of body
weight gain and the increased fat mobilization from WAT
due to fenoﬁbrate-induced increases of fat catabolism in
the liver, but also a strong correlation between reduced
body weight and decreased WAT mass by fenoﬁbrate. In
addition, fenoﬁbrate did not aﬀect food intake in high fat
diet-induced obese LDLR-null mice. These results suggest
that the increased liver activity may be paralleled by a large
reductioninWATmass,whichaccountsformostofthebody
weight reduction.
Fenoﬁbrate also substantially decreased the increases in
circulating triglycerides and total cholesterol levels, indi-
cating that fenoﬁbrate eﬃciently regulates triglyceride and
cholesterol metabolism in male LDLR-null mice. Circu-
lating triglyceride levels are thought to be regulated by
the balance between its secretion and clearance. With
lipoproteincatabolismsuppressed,theincreaseincirculating
triglycerides over time is indicative of the rate at which
triglyceride is being secreted from the liver [84–86]. The10 PPAR Research
hepatic triglyceride secretion rate was signiﬁcantly lower in
fenoﬁbrate-treated mice when Triton WR1339 was used to
preventlipolysis.Theseobservationssuggestthatthereduced
circulating triglyceride levels after fenoﬁbrate treatment are
due to the decreased secretion of triglycerides from the liver.
The molecular mechanisms underlying the eﬀects of
fenoﬁbrate on obesity and lipid metabolism involve the
changes in the expression of apolipoprotein C-III (apo C-
III) and ACOX. LDLR-null mice fed fenoﬁbrate showed
signiﬁcantly lower mRNA levels of hepatic apo C-III, an
apolipoprotein that limits tissue triglyceride clearance [87,
88]. Fenoﬁbrate-activated PPARα in the liver increased
mRNA levels of ACOX, the ﬁrst and rate-limiting enzyme of
PPARα-mediated FA β-oxidation, which resulted in reduced
triglyceride production [87].
In conclusion, fenoﬁbrate prevents both obesity and
hypertriglyceridemia through hepatic PPARα activation in
male LDLR-deﬁcient mice.
3.3. Fenoﬁbrate Regulates Female Obesity Depending on the
Presence of Ovaries. Based on the suggestion that fenoﬁbrate
inhibits body weight gain and adiposity in male LDLR-
null mice, it can be hypothesized that fenoﬁbrate improves
o b e s i t yi nf e m a l eL D L R - n u l lm i c e .B o d yw e i g h tg a i na n d
WAT mass were signiﬁcantly increased in both female OVX
and sham-operated (Sham) LDLR-null mice on a high fat
diet for 8 weeks. The increases in body weight and WAT mass
were higher in female OVX LDLR-null mice than in Sham
mice. Interestingly, fenoﬁbrate-treated female OVX LDLR-
null mice had lower body weights and WAT mass, similar
to those found in several animal models, while female Sham
mice did not exhibit these fenoﬁbrate-induced reductions
[21]. In db/db mice and fatty Zucker rats, the eﬀect of
fenoﬁbrate on body weight depends on the utilization of FA,
as demonstrated by a fenoﬁbrate-induced increase of ACOX
mRNA [9]. PPARα-mediated FA β-oxidation and hydrolysis
of triglycerides by fenoﬁbrate contribute to decreased body
weight and WAT mass in OVX LDLR-null mice, suggesting
that fenoﬁbrate can act as a body weight-regulator in an
animal model of postmenopausal women.
Serum triglycerides and total cholesterol were signiﬁ-
cantly increased in both female OVX and Sham LDLR-null
mice. However, fenoﬁbratetreatment substantiallydecreased
high fat diet-induced increases of triglycerides and choles-
terol in both female groups [9, 87]. In parallel with serum
triglyceride levels, fenoﬁbrate upregulated hepatic ACOX
mRNA levels and downregulated apo C-III mRNA levels in
both OVX and Sham LDLR-null mice [87, 88]. Such changes
in mRNA levels of ACOX by fenoﬁbrate were greater in
female OVX LDLR-null mice than in Sham LDLR-null mice
with functioning ovaries.
However, it is not likely that the PPARα-mediated
reduction in serum triglycerides directly controls obesity in
female Sham LDLR-null mice, which exhibited simultaneous
decreases in serum triglycerides and increases in body weight
and WAT mass. Thus, the eﬀect of fenoﬁbrate on the body
weight of female Sham LDLR-null mice cannot be explained
s i m p l yi nt e r m so fa na l t e r e da n de n h a n c e dﬂ u xo fF A sa n d
triglycerides, since fenoﬁbrate increased ACOX mRNA and
decreased apo C-III gene expression in this group (although
thisexpressionwaslowerthanintheOVXgroup).Moreover,
these changes in ACOX and apo C-III mRNA did not
correlate with increased body weight and adiposity. Such
conﬂicting data suggest the possibility that this discordance
may be caused by ovarian factors.
The regulation of obesity by fenoﬁbrate in female wild-
type C57BL/6J mice is similar to that in female LDLR-null
mice. Fenoﬁbrate reduced body weight gain and WAT mass
in high fat diet-fed wild-type OVX mice but failed to do
so in Sham mice (Figure 5(a))[ 23]. Body weights of OVX
mice were found to be higher than those of Sham mice 6
weeks after commencing the high fat diet. Compared to high
fat diet-fed OVX mice, fenoﬁbrate-treated OVX mice had
signiﬁcantly decreased body weight gain by 6 weeks into the
treatment regimen and had signiﬁcantly lower body weight
at 13 weeks. In addition to changes in body weight, WAT
mass was signiﬁcantly reduced after fenoﬁbrate treatment,
and the ﬁnal WAT mass of the fenoﬁbrate-treated OVX
animals was lower than that of the OVX animals on a regular
chow diet. In contrast to the OVX mice, fenoﬁbrate did
not decrease body weight gain and WAT mass increases in
Sham mice. These results suggest that obesity is diﬀerentially
aﬀected by fenoﬁbrate treatment in Sham and OVX mice.
Fenoﬁbrate reportably acts as a weight-stabilizer through
PPARα although these results were obtained using male
animalmodels[9–11,22].Nevertheless,thesereportssuggest
thatfenoﬁbratenot only prevents excessive weight gainbutis
also able to mobilize fat from adipose tissue by increasing fat
catabolism in the liver. Notably, reductions in body weight
gain and WAT mass by fenoﬁbrate were similar in male and
female OVX mice but were absent in female Sham mice.
Fenoﬁbrate seems to diﬀerentially aﬀect body weight and
adiposity amongOVXandShammicebyamechanismother
than the modulation of leptin gene expression. Although
leptin is produced only in adipose tissue and elicits satiety
responses by binding to leptin receptors in the brain [89, 90],
changes in leptin mRNA levels are in accordance with those
in body weight and WAT mass in both female OVX and
Sham mice following fenoﬁbrate treatment. Consistent with
this ﬁnding, Guerre-Millo et al. [10] reported that serum
leptin concentrations positively correlated with body weight
and epididymal adipose tissue mass in fenoﬁbrate-treated
male mice [10], suggesting that fenoﬁbrate modulates body
weight, not by inﬂuencing leptin gene expression and food
intake, but by enhancing energy expenditure [91, 92].
Diﬀerences in PPARα target gene expression seem
to explain the diﬀerent eﬀects of fenoﬁbrate on gonad-
dependent weight gain in females (Figure 5(b)). Fenoﬁbrate
not only elevated the transcriptional activation of PPARα
target genes, ACOX, HD, and thiolase but also reduced apo
C-III mRNA levels compared to a high fat diet alone in both
groups of mice. Moreover, these alterations in expression
levels were found to be more prominent in female OVX
mice than in Sham mice after fenoﬁbrate treatment. Thus,
fenoﬁbrate inﬂuences obesity via the diﬀerential activation
of PPARα.
It has also been reported that ovarian steroids can
aﬀect obesity and lipid metabolism and that these eﬀectsPPAR Research 11
are likely mediated by estrogens [12]. E2 insuﬃciency is
thought to be largely responsible for increased adiposity
and circulating lipids in OVX rodents because such animals
do not display obesity, adiposity, and lipid disorders when
they are administered E2 replacement [17–19]. Although
the administration of E2 or fenoﬁbrate alone eﬀectively
reduces body weight gain and WAT mass in high fat diet-
fedfemaleOVXmice,fenoﬁbratetreatmentdoesnotprevent
them in female Sham mice with functioning ovaries. These
results suggest the possibility that signal cross-talk may exist
between PPARα and ERs in their eﬀects on obesity and that
the action of fenoﬁbrate may be inﬂuenced by estrogens in
females [25, 27, 93].
In conclusion, treatment with fenoﬁbrate has diﬀerent
eﬀects on body weight and WAT mass due in part to
diﬀerentially activating hepatic β-oxidation and apo C-III
gene expression between female Sham and OVX mice. These
diﬀerences may provide important information about the
mechanisms modulating obesity and about the actions of
other lipid lowering drugs, such as fenoﬁbrate, which are
PPARα ligands in females.
3.4. The Actions of PPARα o nO b e s i t yA r eI n h i b i t e db y
Estrogens. My previous results show that the PPARα ligand
fenoﬁbrate reduced body weight gain and adiposity in
male and female OVX mice, but not in female mice with
functioning ovaries [20–23], suggesting that the actions of
fenoﬁbrate on obesity are inﬂuenced by E2.
E2 aﬀects the ability of fenoﬁbrate to reduce body
weight gain and adiposity in female OVX mice. Mice fed
a high fat diet with either fenoﬁbrate or E2 for 13 weeks
exhibited signiﬁcant decreases in body weight gain and
WAT mass compared to high fat diet-fed controls. These
observations are supported by my previous results showing
that fenoﬁbrate stimulates hepatic FA β-oxidation in female
OVX mice [21, 23], as well as by other reports showing that
E2 inhibits feeding by decreasing meal size in OVX animals
[94, 95]. However, these reductions were not enhanced
when mice were concomitantly treated with fenoﬁbrate and
E2, indicating that E2 may inhibit the function of PPARα
in female obesity [32]. Evidence from both humans and
laboratory animals show that E2 plays an important role
in regulating body weight and WAT mass. Ovariectomy in
rodents increases WAT mass, and E2 replacement decreases
WAT mass [94]. Similarly, while postmenopausal women
have increased body weight gain and WAT weight, E2
decreases both of these [96, 97]. Other studies have also
suggested that fenoﬁbrate reduces body weight gain in male
animal models [9–11] but does not induce decreases in body
weight and WAT mass gains in female mice [20, 21, 23],
suggesting that E2 may inhibit the actions of fenoﬁbrate on
body weight and WAT mass in female OVX mice.
Similarly, the combination of E2 and fenoﬁbrate did not
result in any additional beneﬁcial eﬀects on lipid metabolism
in female OVX mice. While serum levels of total cholesterol
and triglycerides were lowered in mice fed a high fat diet
with either fenoﬁbrate or E2 compared with mice fed a
high fat diet alone [9, 18], the combination of E2 and
fenoﬁbrate increased levels of circulating total cholesterol
and triglycerides compared with either E2 or fenoﬁbrate
alone. These results are in agreement with ﬁndings that
the combination of a lipid-lowering ﬁbrate and hormone
replacement therapy (HRT) for 3 months not only had no
additional beneﬁts on the routine serum lipid or lipopro-
tein proﬁles in overweight postmenopausal women with
elevated triglycerides but also increased serum triglycerides
[97]. Consistent with the circulating lipid metabolism, the
fenoﬁbrate-induced decrease in hepatic lipid accumulation
was also increased by E2 in female OVX mice. Mice fed a
highfatdietshowedconsiderablehepaticlipidaccumulation,
which was prevented by fenoﬁbrate or E2. In contrast, mice
concomitantly treated with fenoﬁbrate and E2 showed an
accumulation of triglyceride droplets. Thus, it appears that
E2 inhibits fenoﬁbrate-induced increases in fat catabolism
in the liver of female OVX mice. Fenoﬁbrate-treated OVX
micewerefoundtohavesimilarfoodintaketoShamcontrols
whereas OVX mice given E2 showed decreased food intake.
However, a combinational treatment of fenoﬁbrate and E2
increased body weight gain, fat weight, and hepatic fat
accumulation compared with fenoﬁbrate alone, despite sim-
ilar food consumption proﬁles between E2 and fenoﬁbrate
plus E2 groups, suggesting that E2 may aﬀect the ability of
fenoﬁbrate to regulate energy balance.
Fenoﬁbrate-activated PPARα has been shown to regulate
the expression of a number of genes critical for FA β-
oxidation and lipid catabolism. Fenoﬁbrate upregulated
ACOX, HD, and thiolase mRNA levels whereas E2 downreg-
ulated the transcriptional activation of these genes. Coad-
ministration of fenoﬁbrate and E2 signiﬁcantly decreased
ACOX, HD, and thiolase mRNA levels compared with
fenoﬁbrate treatment. These results were in accordance with
serum levels of triglycerides and total cholesterol as well as
body weight and WAT mass. Thus, inhibition of the actions
of PPARα on body weight, WAT mass, and circulating lipid
levels by E2 may be attributed, in part, to reductions in
hepatic mRNA expression of PPARα-mediated peroxisomal
FA β-oxidizing enzymes by E2.
Consistent with the in vivo data, E2 inhibited basal
PPARα reporter gene activity as well as Wy14,643-induced
reporter gene activation in NMu2Li murine liver cells
transfected with PPARα, showing that E2 can modulate
PPARα transactivation (Figure 6(a)). The inhibitory activity
by E2 is mediated through its binding to endogenous ERs
that are normally expressed in NMu2Li liver cells since
it is reported that E2 does not bind directly PPARs [98].
However, the possibility that E2 directly binds to PPARα
and inhibits PPARα function cannot be excluded, because
no binding studies have been performed. In cells transfected
with either ERα or ERβ, ERs inhibited the basal expression of
PPRE-mediated reporter gene activity (Figure 6(b)). These
inhibitory eﬀects were signiﬁcantly increased by E2 treat-
ment. This is supported by results showing that PPARs can
regulate ER target gene expression and that signal cross-talk
betweenERsandPPARshasbeenreportedtobebidirectional
[24–26, 28, 93].
Mechanistic studies revealed that the E2-ER complex
was not likely to be competent for PPARα transactivation,
as indicated by the inability of E2 to stimulate PPARα12 PPAR Research
recruitment of coactivators such as CBP (Figure 6(c)).
Ligand-induced conformational changes that allow recruit-
ment of coactivators, such as CBP and the dissociation of
corepressors such as NCoR, are obligatory for transactiva-
tion by PPARα. Treatment of transfected CV-1 cells with
Wy14,643 caused eﬃcient CBP recruitment as evidenced
by an increase in luciferase reporter gene activity. However,
E2 signiﬁcantly decreased Wy14,643-induced CBP associa-
tion in the presence of ERα or ERβ. Thus, inhibition of
PPARα transactivation by ERs was due to competition for
coactivators, increased availability of corepressors, or some
other mechanism. [26, 28] It has previously been shown
that competition of distinct nuclear receptor for coactivator
binding results in a negative cross-talk between nuclear
receptors [99, 100]. These results suggest that E2 inhibition
of PPARα function occurs by impairing the recruitment of
transcriptional coactivators.
PPARα and ERs bind to short DNA sequences termed
HREs, ERE for ERs and PPRE for PPARα [54, 101]. An
ERE is an inverted repeat containing three intervening
bases (AGGTCA N3 TGACCT) whereas a PPRE is a direct
repeat with one or two intervening sequences (AGGTCA
N1,2 AGGTCA). Nonetheless, these sequences contain an
AGGTCA half site, which could be recognized by either ERs
or PPARα. Signal cross-talk between PPAR/RXR and ERs has
been reported to occur through competitive binding to ERE
[24]. Therefore, the inhibition of PPARα transactivation by
ERs may also have been due to their competition for PPRE.
In conclusion, in vivo and in vitro studies demonstrate
that E2 inhibits the actions of PPARα on obesity through
its eﬀects on hepatic PPARα -dependent regulation of target
genes and that these processes are mediated by inhibition
of PPARα recruitment of coactivators by E2-activated ERs
(Figure 7). PPARα l i g a n d sﬁ b r a t e sm a ya c ta se ﬃcient
weight controllers under estrogen-free conditions. Although
E2 alone decreases body weight gain and WAT mass, E2
may impair PPARα actions on obesity. Thus, these results
provide a rationale for the use of fenoﬁbrate in men and
postmenopausal women with obesity and lipid disorder, but
not for premenopausal women with functioning ovaries.
4. Conclusion
Obesity is the leading cause of the metabolic diseases
including type 2 diabetes, atherosclerosis, and hypertension.
PPARα has been the subject of intense academic and phar-
maceutical research because of its ability to improve obesity-
related metabolic disorders. The PPARα ligand fenoﬁbrate
seemstoexhibitanantiobesityeﬀectthroughFAβ-oxidation
inanimalmodelsalthoughsuchaneﬀectofPPARαactivators
has not yet been reported in humans. However, this idea
is supported by several human studies showing that obese
patients with impaired fat oxidation failed to lose weight,
suggesting that elevated fat oxidation leads to weight loss.
Interestingly, there is a sex diﬀerence in the control of
obesity by fenoﬁbrate. Fenoﬁbrate regulates body weight and
adiposity with sexual dimorphism in nutritionally induced
obese male mice. Moreover, fenoﬁbrate-induced reductions
in body weight gain and WAT mass in male mice were
also shown by female OVX mice, but these eﬀects were
absent in female Sham mice, suggesting the involvement of
ovarian hormones in the diﬀerential regulation of obesity
among these groups. In OVX mice, E2 inhibited the actions
of fenoﬁbrate-activated PPARα on obesity, due in part to
reductions in hepatic expression of PPARα-mediated FA β-
oxidizing enzymes by E2, a process mediated through the
inhibition of PPARα coactivator recruitment by E2. These
results provide a mechanism to explain why fenoﬁbrate
reduces body weight gain and adiposity in males and OVX
femalemicebutdoesnotregulateobesityinfemalemicewith
functioning ovaries.
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